Cue Biopharma is trading 5.3% down at $31.11 during live trading on September 25, 2026, with no clear company-specific catalyst identified. - Its latest major announcement was positive September 20 Phase 2 data for CUE-221 in chronic spontaneous urticaria. - The data included statistically significant primary and key secondary endpoints, with favorable safety; the announcement does not explain today’s decline.